Celltrion and iProgen Biotech announce partnership for development of novel ADCs

On April 8, Celltrion and the Canada-based iProgen Biotech Inc. announced to agree to partner for the development of novel ADCs against validated antibody targets, including HER2 and CD20.

From https://www.news-medical.net/news/20190408/Celltrion-and-iProgen-Biotech-announce-partnership-for-development-of-novel-ADCs.aspx

from
https://healthnews010.wordpress.com/2019/04/08/celltrion-and-iprogen-biotech-announce-partnership-for-development-of-novel-adcs/